Using a web-based system , we randomly assigned patients who met full inclusion criteria after screening ( 1:1 ; random permuted block length four ) to celgosivir ( initial 400 mg loading dose within 6 h of randomisation , followed by 200 mg every 12 h for a total of nine doses ) or matched placebo .